Literature DB >> 8565784

Comparison of purified human and rabbit serum paraoxonases.

C L Kuo1, B N La Du.   

Abstract

Rabbit serum paraoxonase (PON) activity was reported to be nearly 20 times greater than that found for humans and all other mammalian species tested, to date. However, 85% of the amino acid residues are identical in human and rabbit PONs, and the two purified PONs show similar substrate specificity patterns. Both are stimulated by phospholipids and have two asparagine-linked sugar chains. Both also have one intramolecular disulfide bond and one free sulfhydryl residue per molecule. Both require Ca2+ for stability and for catalytic activity. Zn2+ and Cd2+ also stabilize both PONs and prevent irreversible denaturation, but neither metal confers catalytic activity. Maximum specific activities for both esterases were approximately 2,000 units of arylesterase activity/mg protein. In contrast, rabbit PON is more stable than human PON to heat inactivation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis treatment. Chelex 100 strips Ca2+ from human PON more easily, and EDTA is less inhibitory with rabbit PON. We conclude that human and rabbit PONs have very similar active centers, but the latter binds Ca2+ more tightly, is a more stable enzyme, and is maintained at 3- to 4-fold higher steady-state concentrations in serum than its human counterpart. PON activity depends on adequate Ca2+ being available; therefore, apparently much higher levels of PON activity in rabbits can be explained by the reduced Ca2+ concentrations present in the early assay methods.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8565784

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Role of calcium ions in the structure and function of the di-isopropylfluorophosphatase from Loligo vulgaris.

Authors:  J Hartleib; S Geschwindner; E I Scharff; H Rüterjans
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

2.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.

Authors:  Amir Aharoni; Leonid Gaidukov; Shai Yagur; Lilly Toker; Israel Silman; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

3.  Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound.

Authors:  Cheon Ho Park; Su Duy Nguyen; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2006-04       Impact factor: 1.880

Review 4.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

5.  Protective action of CLA against oxidative inactivation of paraoxonase 1, an antioxidant enzyme.

Authors:  Nguyen-Duy Su; Xi-Wen Liu; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2003-06       Impact factor: 1.880

6.  Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone.

Authors:  John F Teiber; Sven Horke; Donovan C Haines; Puneet K Chowdhary; Junhui Xiao; Gerald L Kramer; Robert W Haley; Dragomir I Draganov
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

7.  Effects of orange juice and hesperetin on serum paraoxonase activity and lipid profile in hyperuricemic rats.

Authors:  Fatemeh Haidari; Mohammad-Reza Rashidi; Majid Mohammad-Shahi
Journal:  Bioimpacts       Date:  2012-03-17

Review 8.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

9.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17

10.  A common mutation in paraoxonase-2 results in impaired lactonase activity.

Authors:  David A Stoltz; Egon A Ozer; Thomas J Recker; Miriam Estin; Xia Yang; Diana M Shih; Aldons J Lusis; Joseph Zabner
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.